Does MOLNUPIRAVIR Cause Product use in unapproved indication? 296 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 296 reports of Product use in unapproved indication have been filed in association with MOLNUPIRAVIR (LAGEVRIO). This represents 6.2% of all adverse event reports for MOLNUPIRAVIR.
296
Reports of Product use in unapproved indication with MOLNUPIRAVIR
6.2%
of all MOLNUPIRAVIR reports
3
Deaths
14
Hospitalizations
How Dangerous Is Product use in unapproved indication From MOLNUPIRAVIR?
Of the 296 reports, 3 (1.0%) resulted in death, 14 (4.7%) required hospitalization, and 4 (1.4%) were considered life-threatening.
Is Product use in unapproved indication Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for MOLNUPIRAVIR. However, 296 reports have been filed with the FAERS database.
What Other Side Effects Does MOLNUPIRAVIR Cause?
Product use issue (706)
No adverse event (614)
Covid-19 (396)
Wrong technique in product usage process (380)
Diarrhoea (259)
Accidental underdose (207)
Product use complaint (206)
Rash (200)
Underdose (183)
Nausea (180)
What Other Drugs Cause Product use in unapproved indication?
DUPILUMAB (33,452)
DICLOFENAC (12,197)
METHOTREXATE (8,930)
PREDNISONE (7,625)
RITUXIMAB (7,519)
MYCOPHENOLATE MOFETIL (5,910)
ACETAMINOPHEN (5,819)
CYCLOPHOSPHAMIDE (5,750)
RISPERIDONE (5,551)
TACROLIMUS (5,057)
Which MOLNUPIRAVIR Alternatives Have Lower Product use in unapproved indication Risk?
MOLNUPIRAVIR vs MOLSIDOMINE
MOLNUPIRAVIR vs MOMELOTINIB
MOLNUPIRAVIR vs MOMETASONE
MOLNUPIRAVIR vs MOMETASONE FUROATE
MOLNUPIRAVIR vs MOMETASONE FUROATE\OLOPATADINE